154 related articles for article (PubMed ID: 38690276)
1. Progressive sarcopenia and myosteatosis predict prognosis of advanced HCC patients treated with immune checkpoint inhibitors.
Liu M; Jin Q; Wang H; Li Y
Front Immunol; 2024; 15():1396927. PubMed ID: 38690276
[TBL] [Abstract][Full Text] [Related]
2. Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma.
Chen BB; Liang PC; Shih TT; Liu TH; Shen YC; Lu LC; Lin ZZ; Hsu C; Hsu CH; Cheng AL; Shao YY
Eur Radiol; 2023 Jan; 33(1):512-522. PubMed ID: 35864351
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the influence of sarcopenia and myosteatosis on clinical outcomes in gastric cancer patients undergoing immune checkpoint inhibitor.
Deng GM; Song HB; Du ZZ; Xue YW; Song HJ; Li YZ
World J Gastroenterol; 2024 Feb; 30(8):863-880. PubMed ID: 38516238
[TBL] [Abstract][Full Text] [Related]
4. The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors.
Sun W; Yin X; Liu X; Wei J; Yu M; Li W; Ding X; Chen J
Front Immunol; 2024; 15():1380477. PubMed ID: 38698848
[TBL] [Abstract][Full Text] [Related]
5. Body composition predicts prognosis of hepatocellular carcinoma patients undergoing immune checkpoint inhibitors.
Xiong B; Fu B; Wu Y; Gao F; Hou C
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11607-11617. PubMed ID: 37400572
[TBL] [Abstract][Full Text] [Related]
6. Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.
Akce M; Liu Y; Zakka K; Martini DJ; Draper A; Alese OB; Shaib WL; Wu C; Wedd JP; Sellers MT; Bilen MA; El-Rayes BF
Am J Clin Oncol; 2021 Feb; 44(2):74-81. PubMed ID: 33350681
[TBL] [Abstract][Full Text] [Related]
7. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma.
Fujiwara N; Nakagawa H; Kudo Y; Tateishi R; Taguri M; Watadani T; Nakagomi R; Kondo M; Nakatsuka T; Minami T; Sato M; Uchino K; Enooku K; Kondo Y; Asaoka Y; Tanaka Y; Ohtomo K; Shiina S; Koike K
J Hepatol; 2015 Jul; 63(1):131-40. PubMed ID: 25724366
[TBL] [Abstract][Full Text] [Related]
8. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
[TBL] [Abstract][Full Text] [Related]
9. Rapidly declining skeletal muscle mass predicts poor prognosis of hepatocellular carcinoma treated with transcatheter intra-arterial therapies.
Kobayashi T; Kawai H; Nakano O; Abe S; Kamimura H; Sakamaki A; Kamimura K; Tsuchiya A; Takamura M; Yamagiwa S; Terai S
BMC Cancer; 2018 Jul; 18(1):756. PubMed ID: 30041616
[TBL] [Abstract][Full Text] [Related]
10. Different computed tomography parameters for defining myosteatosis in patients with advanced non-small cell lung cancer.
Zhang W; Tang J; Tang H; Xie L; Wang J; Wu J; Yang M
Clin Nutr; 2023 Dec; 42(12):2414-2421. PubMed ID: 37871482
[TBL] [Abstract][Full Text] [Related]
11. Association of myosteatosis with treatment response and survival in patients with hepatocellular carcinoma undergoing chemoembolization: a retrospective cohort study.
Bannangkoon K; Hongsakul K; Tubtawee T; Ina N; Chichareon P
Sci Rep; 2023 Mar; 13(1):3978. PubMed ID: 36894658
[TBL] [Abstract][Full Text] [Related]
12. Nutritional status and skeletal muscle status in patients with head and neck cancer: Impact on outcomes.
Findlay M; White K; Brown C; Bauer JD
J Cachexia Sarcopenia Muscle; 2021 Dec; 12(6):2187-2198. PubMed ID: 34676673
[TBL] [Abstract][Full Text] [Related]
13. The predictive value of sarcopenia and myosteatosis in trans-arterial (chemo)-embolization treated HCC patients.
Long J; Zhang X; Mi W; Shi J; Ren H; Wang Q
Aging (Albany NY); 2024 Jan; 16(1):389-401. PubMed ID: 38189812
[TBL] [Abstract][Full Text] [Related]
14. Model containing sarcopenia and visceral adiposity can better predict the prognosis of hepatocellular carcinoma: a multicenter study.
Liu Y; Fu S; Yu X; Zhang J; Zhu S; Yang Y; Huang J; Luo H; Tang K; Zheng Y; Zhao Y; Chen X; Zhan M; He X; Li Q; Duan C; Chen Y; Lu L
BMC Cancer; 2023 Oct; 23(1):969. PubMed ID: 37828461
[TBL] [Abstract][Full Text] [Related]
15. Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer.
Xu MC; Huelster HL; Hatcher JB; Avulova S; Stocks BT; Glaser ZA; Moses KA; Silver HJ
J Urol; 2021 Mar; 205(3):800-805. PubMed ID: 33080148
[TBL] [Abstract][Full Text] [Related]
16. Body Composition as an Independent Predictive and Prognostic Biomarker in Advanced Urothelial Carcinoma Patients Treated with Immune Checkpoint Inhibitors.
Martini DJ; Shabto JM; Goyal S; Liu Y; Olsen TA; Evans ST; Magod BL; Ravindranathan D; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Joshi SS; Kissick HT; Ogan KE; Harris WB; Kucuk O; Carthon BC; Master VA; Bilen MA
Oncologist; 2021 Dec; 26(12):1017-1025. PubMed ID: 34342095
[TBL] [Abstract][Full Text] [Related]
17. The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 study.
Yang CX; Pan YX; Ye F; Zhu XD; Xue J; Li X; Yuan ZG; Zhang L; Xu L; Chen YJ; Wang NY; Sun HC; Liu XF;
Front Immunol; 2024; 15():1310239. PubMed ID: 38711515
[TBL] [Abstract][Full Text] [Related]
18. Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.
Nowak S; Kloth C; Theis M; Marinova M; Attenberger UI; Sprinkart AM; Luetkens JA
Eur Radiol; 2024 Jan; 34(1):279-286. PubMed ID: 37572195
[TBL] [Abstract][Full Text] [Related]
19. Effect of muscle depletion on survival in peripheral arterial occlusive disease: Quality over quantity.
Vedder IR; Levolger S; Dierckx RAJO; Zeebregts CJ; de Vries JPM; Viddeleer AR; Bokkers RPH
J Vasc Surg; 2020 Dec; 72(6):2006-2016.e1. PubMed ID: 32330596
[TBL] [Abstract][Full Text] [Related]
20. Use of computed tomography-derived body composition to determine the prognosis of patients with primary liver cancer treated with immune checkpoint inhibitors: a retrospective cohort study.
Xiao LS; Li RN; Cui H; Hong C; Huang CY; Li QM; Hu CY; Dong ZY; Zhu HB; Liu L
BMC Cancer; 2022 Jul; 22(1):737. PubMed ID: 35794525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
